NYSE$JNJ
Johnson & Johnson · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Johnson & Johnson reported Q3 2025 sales of $24.0B with net earnings of $5.2B and diluted EPS of $2.12.
Sales to customers were $24.0 billion for the quarter ended September 28, 2025, with net earnings of $5.2 billion and diluted EPS of $2.12. Innovative Medicine and MedTech performance, together with portfolio actions, shaped consolidated results.
- Q3 sales $24.0B; net earnings $5.2B; diluted EPS $2.12.
- Innovative Medicine and MedTech remain core growth engines.
- R&D investment supports oncology, immunology, and med-tech pipelines.
- Other income and tax items affected year-over-year comparability.
Headline financials
Revenue & EPS history
Johnson & Johnson · Revenue · Quarterly
$24B
Revenue by segment
Johnson & Johnson · $19.9B total across 2 segments · Q1 2023
- Innovative Medicine$13.2B+8.8%66.0%
- MedTech$6.78B+3.0%34.0%
Forward guidance
The release discusses Johnson & Johnson's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.
Tailwinds
- Johnson & Johnson cites demand and execution supporting the near-term outlook.
- Liquidity and balance-sheet capacity support operations and shareholder returns.
Headwinds
- Macro, input costs, and FX may pressure margins quarter to quarter.
- Segment mix and one-time items can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+0.4%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.8%
Avg return
30 days after
54%
37 / 69 earnings
Positive
+7.2%
Q2 2023
Best reaction
-4.1%
Q4 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -1.6% | -3.8% | |
| Q4 2025 | -0.4% | +1.5% | +11.1% | |
| Q3 2025 | +0.1% | +1.2% | +2.3% | |
| Q2 2025 | +0.9% | +2.0% | +3.1% | |
| Q1 2025 | -0.5% | +2.0% | -3.1% | |
| Q4 2024 | -1.9% | +3.2% | +9.6% | |
| Q3 2024 | +1.7% | +2.2% | -6.0% | |
| Q2 2024 | +2.9% | +2.1% | +5.5% | |
| Q1 2024 | -1.9% | +0.2% | +4.5% | |
| Q4 2023 | -2.2% | -1.8% | -1.2% | |
| Q3 2023 | -3.0% | -2.9% | -4.7% | |
| Q2 2023 | +7.2% | +8.6% | +8.7% | |
| Q1 2023 | -1.9% | -1.8% | -4.3% | |
| Q4 2022 | +0.7% | -0.0% | -6.3% | |
| Q3 2022 | -1.1% | +1.3% | +5.0% | |
| Q2 2022 | -2.0% | -1.2% | -4.3% | |
| Q1 2022 | +3.5% | +2.2% | -2.1% | |
| Q4 2021 | +3.3% | +5.4% | -3.0% | |
| Q3 2021 | +2.3% | +2.2% | +1.4% | |
| Q2 2021 | +0.9% | +2.0% | +6.5% | |
| Q1 2021 | +2.4% | +1.7% | +5.2% | |
| Q4 2020 | +1.1% | -1.7% | -1.9% | |
| Q3 2020 | -2.5% | -2.5% | -2.3% | |
| Q2 2020 | +0.7% | +1.0% | -0.0% | |
| Q1 2020 | +5.6% | +8.8% | +5.6% | |
| Q4 2019 | -0.5% | -0.3% | +0.4% | |
| Q3 2019 | +3.4% | -2.3% | +0.2% | |
| Q2 2019 | -2.1% | -3.3% | -3.1% | |
| Q1 2019 | +1.5% | +0.7% | +1.2% | |
| Q4 2018 | -1.4% | -1.9% | +3.6% | |
| Q3 2018 | +4.1% | +3.8% | +7.9% | |
| Q2 2018 | +2.5% | +0.9% | +6.2% | |
| Q1 2018 | -3.1% | -3.9% | -6.0% | |
| Q4 2017 | -4.1% | -1.9% | -12.3% | |
| Q3 2017 | +3.3% | +4.6% | +2.0% | |
| Q2 2017 | +2.3% | +2.4% | +0.7% | |
| Q1 2017 | -3.5% | -3.1% | +1.0% | |
| Q4 2016 | -1.0% | -0.5% | +6.8% | |
| Q3 2016 | -3.3% | -4.3% | -1.6% | |
| Q2 2016 | +1.6% | +1.5% | -2.0% | |
| Q1 2016 | +2.4% | — | — | |
| Q4 2015 | +6.0% | — | — | |
| Q3 2015 | -1.5% | — | — | |
| Q2 2015 | +0.1% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | -2.1% | — | — | |
| Q3 2014 | -0.9% | — | — | |
| Q2 2014 | -3.0% | — | — | |
| Q1 2014 | +1.7% | — | — | |
| Q4 2013 | -0.8% | — | — | |
| Q3 2013 | +1.5% | — | — | |
| Q2 2013 | -0.3% | — | — | |
| Q1 2013 | +2.7% | — | — | |
| Q4 2012 | -0.5% | — | — | |
| Q3 2012 | +3.5% | — | — | |
| Q2 2012 | +1.3% | — | — | |
| Q1 2012 | -1.1% | — | — | |
| Q4 2011 | +2.0% | — | — | |
| Q3 2011 | -0.6% | — | — | |
| Q2 2011 | -1.5% | — | — | |
| Q1 2010 | +2.1% | — | — | |
| Q1 2011 | -0.6% | — | — | |
| Q4 2007 | +0.7% | — | — | |
| Q4 2010 | +0.7% | — | — | |
| Q3 2010 | +1.8% | — | — | |
| Q3 2008 | +1.8% | — | — | |
| Q4 2008 | -1.1% | — | — | |
| Q2 2008 | -1.1% | — | — | |
| Q2 2010 | -1.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro